PL3687567T3 - Środek wiążący skierowany przeciwko adrenomedulinie (adm) do stosowania w terapii lub zapobieganiu objawom choroby - Google Patents
Środek wiążący skierowany przeciwko adrenomedulinie (adm) do stosowania w terapii lub zapobieganiu objawom chorobyInfo
- Publication number
- PL3687567T3 PL3687567T3 PL18781997.4T PL18781997T PL3687567T3 PL 3687567 T3 PL3687567 T3 PL 3687567T3 PL 18781997 T PL18781997 T PL 18781997T PL 3687567 T3 PL3687567 T3 PL 3687567T3
- Authority
- PL
- Poland
- Prior art keywords
- adrenomedullin
- adm
- illness
- symptoms
- therapy
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192999 | 2017-09-25 | ||
| EP17203370 | 2017-11-23 | ||
| PCT/EP2018/075987 WO2019057992A2 (en) | 2017-09-25 | 2018-09-25 | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3687567T3 true PL3687567T3 (pl) | 2025-04-07 |
Family
ID=63722372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18781997.4T PL3687567T3 (pl) | 2017-09-25 | 2018-09-25 | Środek wiążący skierowany przeciwko adrenomedulinie (adm) do stosowania w terapii lub zapobieganiu objawom choroby |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220227854A1 (enExample) |
| EP (5) | EP4488295A3 (enExample) |
| JP (1) | JP7461875B2 (enExample) |
| KR (2) | KR20250004928A (enExample) |
| CN (2) | CN119215164A (enExample) |
| AU (2) | AU2018335438B2 (enExample) |
| BR (1) | BR112020005450A2 (enExample) |
| CA (1) | CA3076691A1 (enExample) |
| DK (1) | DK3687567T3 (enExample) |
| ES (1) | ES3001197T3 (enExample) |
| FI (1) | FI3687567T3 (enExample) |
| HR (1) | HRP20241795T1 (enExample) |
| HU (1) | HUE069945T2 (enExample) |
| IL (1) | IL273533A (enExample) |
| LT (1) | LT3687567T (enExample) |
| MX (1) | MX2020003538A (enExample) |
| MY (1) | MY204700A (enExample) |
| PL (1) | PL3687567T3 (enExample) |
| RS (1) | RS66415B1 (enExample) |
| SG (1) | SG11202002258WA (enExample) |
| SI (1) | SI3687567T1 (enExample) |
| WO (1) | WO2019057992A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3148275A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| MX2022010207A (es) * | 2020-02-27 | 2022-11-16 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque. |
| BR112022017890A2 (pt) * | 2020-03-16 | 2022-11-01 | Sphingotec Gmbh | Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina |
| CN111893085A (zh) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心（有限合伙） | 一种通过干细胞体外分化获得人工皮肤的方法及其应用 |
| WO2024017331A1 (zh) * | 2022-07-20 | 2024-01-25 | 上海济煜医药科技有限公司 | 一种抗肾上腺髓质素非中和抗体、其制备方法及应用 |
| WO2025152915A1 (zh) * | 2024-01-16 | 2025-07-24 | 上海济煜医药科技有限公司 | 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP2005508623A (ja) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | 改変されたトランスフェリン融合タンパク質 |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| SI2506871T1 (sl) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| BR112012014194A2 (pt) | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
| SMT201900297T1 (it) | 2010-06-08 | 2019-07-11 | Astrazeneca Ab | Muteine di lipocalina lacrimale che si legano a il-4 r alfa |
| PL2780370T3 (pl) | 2011-11-16 | 2020-01-31 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta |
| ES2729710T3 (es) * | 2011-11-16 | 2019-11-05 | Adrenomed Ag | Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda |
| PL2594587T3 (pl) * | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry |
| JP6321545B2 (ja) * | 2011-11-16 | 2018-05-09 | アドレノメト アクチェンゲゼルシャフト | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 |
| RS55804B1 (sr) * | 2011-11-16 | 2017-08-31 | Sphingotec Gmbh | Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina |
| EP2976646B1 (en) * | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| US20200299372A1 (en) * | 2016-12-16 | 2020-09-24 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
-
2018
- 2018-09-25 CN CN202411206189.XA patent/CN119215164A/zh active Pending
- 2018-09-25 EP EP24205659.6A patent/EP4488295A3/en active Pending
- 2018-09-25 RS RS20241461A patent/RS66415B1/sr unknown
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/pt unknown
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/ja active Active
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/en active Pending
- 2018-09-25 AU AU2018335438A patent/AU2018335438B2/en active Active
- 2018-09-25 HU HUE18781997A patent/HUE069945T2/hu unknown
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/en active Pending
- 2018-09-25 MY MYPI2020001569A patent/MY204700A/en unknown
- 2018-09-25 DK DK18781997.4T patent/DK3687567T3/da active
- 2018-09-25 LT LTEPPCT/EP2018/075987T patent/LT3687567T/lt unknown
- 2018-09-25 CA CA3076691A patent/CA3076691A1/en active Pending
- 2018-09-25 FI FIEP18781997.4T patent/FI3687567T3/fi active
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/en not_active Ceased
- 2018-09-25 ES ES18781997T patent/ES3001197T3/es active Active
- 2018-09-25 CN CN201880062062.1A patent/CN111511390B/zh active Active
- 2018-09-25 SI SI201831189T patent/SI3687567T1/sl unknown
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/en not_active Withdrawn
- 2018-09-25 PL PL18781997.4T patent/PL3687567T3/pl unknown
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
- 2018-09-25 KR KR1020247040657A patent/KR20250004928A/ko active Pending
- 2018-09-25 HR HRP20241795TT patent/HRP20241795T1/hr unknown
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/ko not_active Ceased
- 2018-09-25 EP EP18781997.4A patent/EP3687567B1/en active Active
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/es unknown
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273533A (en) | Antiadrenomedullin (ADM) binder for use in treating or preventing symptoms of disease | |
| IL256175A (en) | Using exosomes to treat the disease | |
| EP2981274A4 (en) | Probiotic strains for use in treatment or prevention of osteoporosis | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| HUS2400045I1 (hu) | Delgocitinib alkalmazása krónikus kézekcéma kezelésére | |
| SG11201604840TA (en) | Prophylactic and/or therapeutic agent for functional gastrointestinal disorders | |
| PL3197556T3 (pl) | KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII | |
| GB201700526D0 (en) | Therapeutic use | |
| HUE045532T2 (hu) | Preventív és/vagy terápiás szer immunbetegségekre | |
| PL3021858T3 (pl) | Szczep cu1 do leczenia i/lub profilaktyki przewlekłych zapalnych chorób reumatycznych | |
| GB201522329D0 (en) | Use of adjuvants for the prevention and/or treatment of autoimmune diseases | |
| HK40120923A (zh) | 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| SI3548006T1 (sl) | Sestava za uporabo pri zdravljenju črevesnih sprememb | |
| IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
| PT3687567T (pt) | Ligante anti-adrenomedulina (adm) para utilização em terapia ou prevenção de sintomas de doença | |
| PT3191112T (pt) | Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura | |
| EP3222281A4 (en) | Preventive and therapeutic agent for celiac disease | |
| SG10201607658RA (en) | Electronic gaming system adapted for simultaneous use of multiple users | |
| HK1257141A1 (en) | Varlitinib for use in the treatment of resistant or refractory cancer | |
| LT3413894T (lt) | P13k aktyvumo arba funkcijos inhibitorių panaudojimas pirminio sjögren'o sindromo gydymui | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases | |
| GB201702921D0 (en) | Therapeutic agent | |
| GB201516080D0 (en) | Tactile transducer treatment system |